2 results
Approved WMOCompleted
To assess the rates of preliminary response and sustained remission of AASV following rituximab (on the basis of former studies, 86% sustained remission expected with rituximab compared to 75% in control group).To assess safety of a rituximab…
Approved WMOCompleted
To evaluate the tolerability (adverse effects) of 99mTc-Fucoidan in 10 healthy volunteers (phase I).